Pfirrmann, M;Ehninger, G;Thiede, C;Bornhäuser, M;Kramer, M;Röllig, C;Hasford, J;Schaich, M;Study Alliance Leukaemia (SAL);Dörken, B;Huhn, D;Knigge, O;Rick, O;Siegert, W;Hesse-Amojo, J;Kolloch, R;Krümpelmann, U;Pflüger, K-;Wolff, T;Heidtmann, H-;Marquard, F;Hänel, M;Fiedler, F;Herbst, R;Gramatzki, M;Helm, G;Beelen, D;Saal, J-;Arland, M;Finke, J;Fasshauer, E;Zander, A;Schmitz, N;Stuhlmann, R;Schmidt, H;Buhrmann, K;Dürk, H;Burk, M;Ganser, A;Ho, A;Krämer, A;Fauser, A;Kaiser, U;Bartholomäus, A;Link, H;Hagmann, F-;Köchling, G;Schalk, K-;Fetscher, S;Wagner, T;Neubauer, A;Bodenstein, H;Tischler, J;Kolb, H-;Pohlmann, H;Brack, N;Wandt, H;Schäfer-Eckart, K;Seeber, B;Hirsch, F;Geer, T;Heissmeyer, H;Labenz, J;Aulitzky, W;Kaufmann, M;Kaesberger, J;Clemens, M;Mahlberg, R;Kanz, L;Schwerdtfeger, R;Engberding, R;Winter, R;Sandmann, M;Einsele, H;Rückle-Lanz, H;Greiner, L
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Lancet Oncol
2012
13
2
207-14

Moosmann, A;Hammerschmidt, W;Kolb, HJ
Virus-specific T cells for therapy--approaches, problems, solutions.
Eur J Cell Biol
2012
91
1
97-101

Schmid, C;Schleuning, M;Tischer, J;Holler, E;Haude, KH;Braess, J;Haferlach, C;Baurmann, H;Oruzio, D;Hahn, J;Spiekermann, K;Schlimok, G;Schwerdtfeger, R;Buechner, T;Hiddemann, W;Kolb, HJ
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Bone Marrow Transplant
2012
47
1
46-53

Kaufmann, T;Strasser, A;Jost, PJ
Fas death receptor signalling: roles of Bid and XIAP.
Cell Death Differ
2012
19
1
42-50

Höfig, I;Atkinson, MJ;Mall, S;Krackhardt, AM;Thirion, C;Anastasov, N
Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors.
J Gene Med
2012
14
8
549-60

Schmitz, N;Nickelsen, M;Ziepert, M;Haenel, M;Borchmann, P;Schmidt, C;Viardot, A;Bentz, M;Peter, N;Ehninger, G;Doelken, G;Ruebe, C;Truemper, L;Rosenwald, A;Pfreundschuh, M;Loeffler, M;Glass, B;German High-Grade Lymphoma Study Group (DSHNHL);Sezer, O;Ordemann, R;Behringer, D;Brossart, P;Fritsch, G;Pflüger, KH;Hänel, M;Peter, N;Levknecht, C;Ehninger, G;Schlegel, F;Dührsen, U;Weidmann, E;Kiehl, M;Giagounidis, A;Trümper, L;Dölken, G;Lindemann, HW;Appel, T;Schmoll, HJ;Bokemeyer, C;Salwender, H;Schmitz, N;Glass, B;Nickelsen, M;Balleisen, H;Kirchner, H;Kirchner, H;Dreger, P;Tron, V;Kaiser, U;Pfreundschuh, M;Kiehl, M;Bentz, M;Kneba, M;Borchmann, P;Frieling, T;Hartmann, F;Fetscher, S;Brosig, B;Hoffmann, J;Fischer, T;Hofmann, WK;Gräven, U;Schmidt, C;Karthaus, M;Peschel, C;Mesters, R;Falge, C;Müller, H;Gaska, T;Maschmeyer, G;Freund, M;Potratz, J;Hähling, D;Gassmann, W;Kölbel, CB;Clemens, M;Kubin, TW;Viardot, A;Frickhofen, N
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Lancet Oncol
2012
13
12
1250-9

Joensuu, H;Eriksson, M;Sundby Hall, K;Hartmann, JT;Pink, D;Schutte, J;Ramadori, G;Hohenberger, P;Duyster, J;Al-Batran, SE;Schlemmer, M;Bauer, S;Wardelmann, E;Sarlomo-Rikala, M;Nilsson, B;Sihto, H;Monge, OR;Bono, P;Kallio, R;Vehtari, A;Leinonen, M;Alvegård, T;Reichardt, P
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
JAMA
2012
307
12
1265-72

Illert, AL;Zech, M;Moll, C;Albers, C;Kreutmair, S;Peschel, C;Bassermann, F;Duyster, J
Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M.
J Biol Chem
2012
287
45
37997-8005

Illert, Anna Lena;Kawaguchi, Hiroyuki;Antinozzi, Cristina;Bassermann, Florian;Quintanilla-Martinez, Letitia;von Klitzing, Christine;Hiwatari, Mitsuteru;Peschel, Christian;de Rooij, Dirk G;Morris, Stephan W;Barchi, Marco;Duyster, Justus
Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.
Development
2012
139
14
2523-34

Metzelder, SK;Schroeder, T;Finck, A;Scholl, S;Fey, M;Götze, K;Linn, YC;Kröger, M;Reiter, A;Salih, HR;Heinicke, T;Stuhlmann, R;Müller, L;Giagounidis, A;Meyer, RG;Brugger, W;Vöhringer, M;Dreger, P;Mori, M;Basara, N;Schäfer-Eckart, K;Schultheis, B;Baldus, C;Neubauer, A;Burchert, A
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Leukemia
2012
26
11
2353-9